Novavax (NVAX) News Today

Novavax, Inc. (NASDAQ:NVAX) saw its shares react to a flurry of regulatory approvals, analyst updates and product launches over the past 24 hours. Key developments include:

• Positive Sentiment: Novavax won FDA approval for its Nuvaxovid biologics license application (BLA), clearing the way for broader commercialization of its COVID-19 vaccine candidate. Novavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLA
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating on NVAX, setting a $10.00 price target and forecasting Q4 2025 EPS of –$0.37, reflecting analyst confidence in a rebound. HC Wainwright Q4 2025 EPS Estimates
• Positive Sentiment: In the same note, HC Wainwright’s S. Lee projected Q3 2025 EPS of –$0.27 while maintaining the Buy rating and $10 target, underlining long-term optimism. HC Wainwright Q3 2025 EPS Estimates
• Positive Sentiment: For FY 2026, HC Wainwright forecasts EPS of –$0.68 but leaves its “Buy” recommendation and $10 price objective intact, indicating belief in eventual profitability. HC Wainwright FY 2026 EPS Estimates
• Positive Sentiment: Robert Kennedy Jr. announced the end of FDA COVID-19 mandates, explicitly clearing Moderna, Pfizer and Novavax vaccines for high-risk groups, potentially expanding NVAX’s market access. End of FDA COVID Mandates Clears NVAX for High-Risk Groups
• Positive Sentiment: The FDA approved an updated formulation of Nuvaxovid specifically for key high-risk populations, driving NVAX stock higher on optimism for targeted uptake. FDA Approves Updated Nuvaxovid for High-Risk Groups
• Positive Sentiment: HC Wainwright formally initiated coverage on Novavax with a “Buy” rating and $10 price target—implying roughly 34% upside from current levels. HC Wainwright Initiates Coverage
• Positive Sentiment: Novavax launched a protein-based COVID-19 vaccine for high-risk adults, leveraging its Matrix-M adjuvant platform to address unmet needs. NVAX Launches Protein-Based Vaccine
• Positive Sentiment: A Zacks analysis named NVAX a top momentum stock for the long term, highlighting favorable style scores and technical trends. Why Novavax is a Top Momentum Stock
• Negative Sentiment: The FDA’s approval of updated COVID-19 vaccines from Pfizer, Moderna and Novavax comes with restrictions limiting use to older adults and high-risk groups, potentially capping NVAX’s broader market reach. FDA Approves Updated Vaccines With Restrictions